Background: The
success of antiretroviral therapy requires better virological monitoring. We
described the virological profile of patients on combined antiretroviral
therapy (cART) for HIV/AIDS in Bangui, Central African Republic (CAR). Methods: In this prospective cohort study of patients who had been on combined
antiretroviral therapy treatment (cART) for at least 12 months in Bangui, only
one HIV plasma viral load per patient was realized at the Institut Pasteur of
Bangui, between April 4th and November 28th, 2017.Sociodemographic
and biological data were collected. Blood samples were taken for viral load.
The biocentric generic human immunodeficiency virus (HIV) load test was used to
quantify a ribonucleic acid (RNA) HIV-1. Data were analyzed with Stata software
version 14. Chi-squared test was used to analyse viral load according to sex
and age. The level of significance was set at P ≤ 0.05. Results: A total of 3569 patients
were recruited, with a mean age of 40 years (median, 42 years; range, 1 - 84),
patients aged 40 - 49 predominating (34.2%). The sex ratio was 0.4. No virus
was detectable in plasma from 49.2% of patients, while 42.4% had virological
failure (viral load, ≥1000 copies/mL) according to WHO criteria. The risk for
virological failure decreased with age (P = 0.001) and was higher among females than males (P =
0.001). Conclusions: The rate of virological failure
References
[1]
Central African Institute for Statistics and Economic and Social Studies (2010) Multiple Indicator Cluster Surveys.
[2]
Centre de surveillance des déplacements internes (2015). http://www.internal-displacement.org/
[3]
International Federation of Red Cross and Red Crescent Societies. Central African Republic: A Difficult Operational Context—Success Story. https://media.ifrc.org/ifrc/
[4]
Mellors, J.W., Munoz, A., Glori, J.V., Margolick, J.B., Tassoni, C.I., Gupta, P., et al. (1997) Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection. Annals of Internal Medicine, 126, 946-954. https://doi.org/10.7326/0003-4819-126-12-199706150-00003
[5]
Hammer, S.M., Saag, M.S., Schechter, M., Montaner, J.S., Schooley, R.T., Jacobsen, D.M., et al. (2006) Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA, 296, 827-843. https://doi.org/10.1001/jama.296.7.827
[6]
WHO (2017) Information Note: Management of HIV (WHO/VIH/2017.22). Geneva. http://www.who.int/hiv/en/
[7]
WHO (2016) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd Edition, Geneva.
[8]
WHO (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva.
[9]
Mouala, C., Kaba-Mebri, J., Wata, J.B. and Rey, J.L. (2006) Facteurs associés à une bonne observance thérapeutique chez les patients infectés par le VIH à Bangui. Cahiers d’études et de recherches francophones/Santé, 16, 119-130.
[10]
Lozès, E., Ahoussinou, C., Agassounou-Tchibozo Djikpo, M., Dahouegnon, E., Ahossouhe, N., Acoty, A. and de Souza, C. (2012) Variabilité du taux des lymphocytes CD4 et de la charge virale chez les personnes vivant avec le VIH sous traitement antiretroviral: Cas de l’hopital Saint Jean De Dieu de Tanguieta (Benin). International Journal of Biological and Chemical Sciences, 6, 650-656. https://doi.org/10.4314/ijbcs.v6i2.9
[11]
Marchand, C., Himmich, H., Maaroufi, A., Sohier, N., Chambon, J.-F. and Gagnayre, R. (2005) Mise en oeuvre et évaluation d’un programme d’éducation thérapeutique (2000-2001) pour les patients atteints du VIH à Casablanca (Maroc). Cahiers d’études et de recherches francophones/Santé, 15, 73-80.
[12]
Flexor, G., Zucman, D., Berthé, H., Meier, F., Force, G., Greder-Belan, A., et al. (2013) Vieillissement et infection par le VIH: Suivi de 149 patients agés de plus de 60 ans infectés par le VIH (COREVIH Île-de-France Ouest [Ageing and HIV infection: 4 Years’ Follow-Up of 149 HIV-Infected Patients Older than 60 years in West Paris Agglomeration (COREVIH Île-de-France Ouest). La Presse Médicale, 42, e145-e152. https://doi.org/10.1016/j.lpm.2012.11.005
[13]
Amellal, B., Katlama, C. and Calvez, V. (2007) Evaluation of the Use of Dried Spots and of Different Storage Conditions of Plasma for HIV-1 RNA Quantification. HIV Medicine, 8, 396-400. https://doi.org/10.1111/j.1468-1293.2007.00484.x
[14]
Brambilla, D., Jennings, C., Aldrovandi, G., Bremer, J., Comeau, A.M., Cassol, S.A., et al. (2003) Multicenter Evaluation of Use of Dried Blood and Plasma Spot Specimens in Quantitative Assays for Human Immunodeficiency Virus RNA: Measurement, Precision, and RNA Stability. Journal of Clinical Microbiology, 41, 1888-1893. https://doi.org/10.1128/JCM.41.5.1888-1893.2003
[15]
Cassol, S.A., Gill, M.J., Pilon, R., Cormier, M., Voigt, R.F., Willoughby, B., et al. (1997) Quantification of Human Immunodeficiency Virus Type 1 RNA from Dried Plasma Spots Collected on Filter Paper. Journal of Clinical Microbiology, 35, 2795-2801.
[16]
Kane, C.T., Ndiaye, H.D., Diallo, S., Ndiaye, S., Wade, A.S., Diaw, P.A., et al. (2008) Quantitation of HIV-1 RNA in Dried Blood Spots by the Real-Time NucliSENS EasyQ HIV-1 Assay in Senegal. Journal of Virological Methods, 148, 291-295. https://doi.org/10.1016/j.jviromet.2007.11.011
[17]
Mwaba, P., Cassol, S., Nunn, A., Pilon, R., Chintu, C., Janes, M., et al. (2003) Whole Blood Versus Plasma Spots for Measurement of HIV-1 Viral Load in HIV Infected African Patients. The Lancet, 362, 2067-2068. https://doi.org/10.1016/S0140-6736(03)15103-3
[18]
Péré, H., Charpentier, C., Mbelesso, P., Dandy, M., Matta, M., Moussa, S., De Dieu Longo, J., Grésenguet, G., Abraham, B. and Bélec, L. (2012) Virological Response and Resistance Profiles after 24 Months of First-Line Antiretroviral Treatment in Adults Living in Bangui, Central African Republic. AIDS Research and Human Retroviruses, 28, 315-323. https://doi.org/10.1089/aid.2011.0127
[19]
Moussa, S., Pinson, P., Pelembi, P., Gody, J.C., Mbitikon, O., Fikouma, V., Mbay, P. and Fleury, H.J. (2010) First Data on HIV-1 Resistance Mutations to Antiretroviral Drugs in Central African Republic. AIDS Research and Human Retroviruses, 26, 1247-1248. https://doi.org/10.1089/aid.2010.0091
[20]
Charpentier, C., Gody, J.C., Mbitikon, O., Moussa, S., Matta, M., Péré, H., Fournier, J., Longo, J.D.D. and Bélec, L. (2012) Virological Response and Resistance Profiles after 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic. AIDS Research and Human Retroviruses, 28, 87-94. https://doi.org/10.1089/aid.2011.0035
[21]
Mossoro-Kpinde, C.D., Gody, J.C., Mboumba Bouassa, R.S., Mbitikon, O., Jenabian, M.A., Robin, L., Matta, M., Zeitouni, K., Longo, J.D., Costiniuk, C., Grésenguet, G., Touré Kane, N.C. and Bélec, L. (2017) High Levels of Virological Failure with Major Genotypic Resistance Mutations in HIV-1-Infected Children after 5 Years of Care according to WHO-Recommended 1st-Line and 2nd-Line Antiretroviral Regimens in the Central African Republic: A Cross-Sectional Study. Medicine, 96, e6282. https://doi.org/10.1097/MD.0000000000006282
[22]
Charpentier, C., Gody, J.C., Tisserand, P., Matta, M., Péré, H., Fournier, J., Mbitikon, O. and Bélec, L.(2011) Surveillance of Antiretroviral Drug Resistance Mutations in Untreated Young Children Living in the Central African Republic. Antiviral Therapy, 16, 1347-1350. https://doi.org/10.3851/IMP1896
[23]
Ellman, T.M., Alemayehu, B., Abrams, E.J., Arpadi, S., Howard, A.A. and El-Sadr, W.M. (2017) Selecting a Viral Load Threshold for Routine Monitoring in Resource-Limited Settings: Optimizing Individual Health and Population Impact. Journal of the International AIDS Society, 20, e25007. https://doi.org/10.1002/jia2.25007
[24]
Panel on Antiretroviral Guidelines for Adults and Adolescents (2016) Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Department of Health and Human Services, Rockville.
[25]
Havir, D.V., Bassett, R., Leviatan, D., Gilbert, P., Tebas, P., Collier, A.C., et al. (2001) Prevalence and Predictive Value of Intermittent Viremia with Combination HIV Therapy. JAMA, 286, 171-179. https://doi.org/10.1001/jama.286.2.171
[26]
Rycavage, P., Kelly, S., Li, J.Z., Harrigan, P.R. and Taiwo, B. (2014) Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 58, 3585-3598. https://doi.org/10.1128/AAC.00076-14
[27]
Taiwo, B., Gallien, S., Aga, E., Ribaudo, H., Haubrich, R., Kuritzkes, D., et al. (2001) Antiretroviral Drug Resistance in HIV-1-Infected Patients Experiencing Persistent Low-Level Viremia during First-Line Therapy. The Journal of Infectious Diseases, 204, 515-520. https://doi.org/10.1093/infdis/jir353
[28]
Aubry, P. (2012) Infection à VIH/SIDA et tropiques, actualités. In: Cours de Médecine Tropicale: Pathologie Infectieuse et Tropicale. http://www.medecinetropicale.com/
[29]
Kebede, A. and Tajure, W.N. (2012) Medication Adherence and Its Determinants among Patients on Concomitant Tuberculosis and Antiretroviral Therapy in South West Ethiopia. North American Journal of Medical Sciences, 4, 67-71. https://doi.org/10.4103/1947-2714.93376
[30]
Potchoo, Y., Tchamdja, K., Balogou, A., Pitche, V.P., Guissou, I.P. and Kassang, E.K. (2010) Knowledge and Adherence to Antiretroviral Therapy among Adult People Living with HIV/AIDS Treated in the Health Care Centers of the Association “Espoir Vie Togo” in Togo, West Africa. BMC Clinical Pharmacology, 10, 11. https://doi.org/10.1186/1472-6904-10-11
